Home Clinical trials For patients Ovary DENALI

DENALI

A phase 2 open-label, multicenter study to evaluate efficacy and safety of ZN-c3 in subjects with high-grade serous ovarian, fallopian tube or primary peritoneal cancer

Open
Trial drug
ZN-c3 (azenosertib)
Grade
High grade
Prior lines
1, 2, 3, 4
Histology
Serous
Platin
Platinum resistant
Secondary platinum refractory
Phase
II

Treatment

The treatment option in this study is ZN-c3 (azenosertib).
ZN-c3 is taken orally.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.